Similarly, the evaluation of the mRNA expression levels of ERBB3 in breast cancer specimens stratified for clinical subtypes demonstrated that the luminal, HER2+, and triple-negative subgroup display the highest, intermediate and lowest levels, respectively (Figure 2b). This evidence concerns the gene ERBB3 and breast carcinoma.